

Stichting Duchenne Data Foundation
Warmoesdreef 10
4614 HC BERGEN OP ZOOM

Ref: 53465/11201/IVL/IVL

De Meern, 8 december 2025

Betreft: Brief aanbidding definitieve jaarrekening 2023

Geacht bestuur,

Hierbij ontvang je de definitieve jaarrekening 2023 van "DDF".

In verband met de privacy-wetgeving sturen wij dit overzicht via PKI signing en verzoeken je hieronder te tekenen voor ontvangst, zodat wij dit in ons dossier kunnen opslaan.

Met vriendelijke groet,

drs. I.M. van Lexmond AA

Voor ontvangst:

A. Bergsma

**STICHTING DUCHENNE DATA FOUNDATION
AT BERGEN OP ZOOM**

Annual Report 2023

December 8, 2025

CONTENTS

Pagina

AUDITOR'S REPORT

1	Engagement	2
2	Accountant's compilation report	2
3	Results	4
4	Financial position	5

MANAGEMENT BOARD REPORT

1	Management board report	7
---	-------------------------	---

FINANCIAL STATEMENTS

1	Balance sheet as at December 31, 2023	16
2	Statement of the financial activities over 2023	18
3	Notes to the financial statements	19
4	Notes to the balance sheet as of December 31, 2023	22
5	Notes to the statement of financial activities 2023	27

OTHER INFORMATION

1	Audit	30
2	Recognition of the loss for 2023	30

AUDITOR'S REPORT

To the management of
Stichting Duchenne Data Foundation
Warmoesdreef 10
4614 HC Bergen op Zoom

<i>Reference</i>	<i>Processed by</i>	<i>Date</i>
11201	HdB-IL	December 8, 2025

Dear members of the Executive Board,

We hereby send you the report regarding the financial statements for the year 2023 of your company.

1 ENGAGEMENT

In accordance with your instructions we have compiled the annual account 2023 of your company, including the balance sheet with counts of € 355,601 and the statement of financial activities with a negative result of € 13,616.

2 ACCOUNTANT'S COMPILATION REPORT

To: the management

The financial statements of Stichting Duchenne Data Foundation at Bergen op Zoom have been compiled by us using the information provided by you. The financial statements comprise the balance sheet as at December 31, 2023 and the profit and loss account for the year 2023 with the accompanying explanatory notes. These notes include a summary of the accounting policies which have been applied.

This compilation engagement has been performed by us in accordance with Dutch law, including the Dutch Standard 4410, "Compilation engagements", which is applicable to accountants. The standard requires us to assist you in the preparation and presentation of the financial statements in accordance with Part 9 of Book 2 of the Civil Code. To this end we have applied our professional expertise in accounting and financial reporting.

In a compilation engagement, you are responsible for ensuring that you provide us with all relevant information and that this information is correct. Therefore, we have conducted our work, in accordance with the applicable regulations, on the assumption that you have fulfilled your responsibility. To conclude our work, we have read the financial statements as a whole to consider whether the financial statements as presented correspond with our understanding of Stichting Duchenne Data Foundation. We have not performed any audit or review procedures which would enable us to express an opinion or a conclusion as to the fair presentation of the financial statements.

During this engagement we have complied with the relevant ethical requirements prescribed by the "Verordening Gedrags- en Beroepsregels Accountants" (VGBA). You and other users of these financial statements may therefore assume that we have conducted the engagement in a professional, competent and objective manner and with due care and integrity and that we will treat all information provided to us as confidential.

For further information on the nature and scope of a compilation engagement and the VGBA we refer you to www.nba.nl/uitleg-samenstellingsverklaring.

2.1 Recognition of the 2022 loss

The result amounting to € 91,687 has been carried forward as accumulated deficit.

3 RESULTS

3.1 Development of income and expenses

The results for 2023 amounts negatief € 13,616 to negatief € 91,687 for 2022. The results for both years can be summarized as follows:

	2023	2022
	€	€
Income		
Income from individuals	188,310	130,000
Subsidies	125,627	34,309
Other income	182,566	177,416
Gross margin	<u>496,503</u>	<u>341,725</u>
Expenditure		
Expenditure on activities	434,086	305,443
Depreciation of tangible fixed assets	618	36
Office expenses	33,160	82,296
General expenses	42,255	44,285
Sum of expenses	<u>510,119</u>	<u>432,060</u>
Resultaat	<u>-13,616</u>	<u>-90,335</u>
Financial income and expenses		
Interest and similar expenses	-	-1,352
Result	<u><u>-13,616</u></u>	<u><u>-91,687</u></u>

4 FINANCIAL POSITION

The balance sheet can be summarized as follows:

	12/31/2023		12/31/2022	
	€	€	€	€
Long term funds:				
Reserves and funds		328,426		342,042
Long term investments:				
Tangible fixed assets		2,435		3,053
Working capital		<u>325,991</u>		<u>338,989</u>

This amount is applied as follows:

Receivables, prepayments and accrued income	69,281		108,148	
Cash and cash equivalents	<u>283,885</u>		<u>280,069</u>	
		353,166		388,217
Debit: Short-term debt		27,175		49,228
Working capital		<u>325,991</u>		<u>338,989</u>

Yours sincerely,
Stolwijk Registeraccountants & Belastingadviseurs B.V.

I.M. van Lexmond AA

MANAGEMENT BOARD REPORT

Activity Report

2023

Contents

Contents

Purpose of this document 3

Composition and roles of Board members 3

Mission and Vision..... 3

Strategy 4

Activities performed in 2023 5

- 1. Administration and management activities 5
- 2. Communication/dissemination activities..... 5
- 3. Projects..... 5

Conclusions..... 8

Purpose of this document

The purpose of this Board Management Report is to present and summarize the activities performed by the Board and employees of the Duchenne Data Foundation (DDF) in 2023. This report will serve as a communication tool to update the current Board members on the work and activities performed and completed in the previous year.

Composition and roles of Board members

The board members are:

- Paliouras, G. (Chair and Director R&D) since 01/01/2020
- Schreur, R. (Director of Finance and Business Development) – From 06/12/2021 to 01/01/2023
- Sheila Vasconcelos (Director of Community Empowerment) – since 01/03/2023
- Ajaikumar, BS. (Director of Clinical Programs) – since 01/10/2021
- Arjen Bergsma (Director of Data Services) – since 01/01/2022

Mission and Vision

Mission and vision

DDF believes that patients should be able to own, control, and share their data. Therefore, DDF fosters multi-source data connection so people living with dystrophinopathies can live their lives to the fullest. By building the missing link between various sources of data, evidence is generated to optimize R&D and care practices.

Our goal is to accelerate the pathway to the development of innovative therapies, improve care and best practices, reduce misinformation and promote participation in the global dystrophinopathy community.

Our mission is to connect the fragmented data in the field of dystrophinopathies and test innovative solutions, scaling them to make a global impact.

Our vision is to bring data to life to improve the world of dystrophinopathies.

Strategy

Strategic direction

The strategic direction of DDF is built around 4 key pillars:

1. Research & Development
2. Standards of Care & Quality of Life
3. Education & Capacity Building
4. Data Equity & Access

Research & Development

DDF connects data to generate new evidence for more efficient research in therapy development and care. The aim is to create an environment of dystrophinopathy data from various sources and locations, following the strict standards of data governance and [‘FAIR’](#) principles. This evidence will inform the development of best care practices and therapies and support and inform regulatory and policy processes. The organization will enable the safe exchange of data and information to inform all areas of research and stakeholders.

Standards of Care & Quality of Life

DDF strives for all people living with dystrophinopathies around the world to have access to the latest standards of care and the best quality of life. This includes early diagnosis and surveillance, alongside quality-of-life initiatives. This will be achieved by collecting and analyzing data related to patient needs and preferences and connecting patients with the services they need.

Education & Training

DDF provides training to all stakeholders. The goal is to empower the global dystrophinopathy community voice to ensure research is patient and family-led and centered. The Duchenne Data Foundation will work alongside the World Duchenne Organization to facilitate the exchange of timely, evidence-based, and accurate information so all stakeholders can make informed decisions. This includes, but is not limited to, training on clinical trials and research, and patients being in control of their data.

Data Governance & Access

People should be able to own, control, and share their data. DDF advocates for people living with dystrophinopathies to achieve this. At the same time, the dystrophinopathy community should be able to benefit from the insights of the data.

Activities performed in 2023

1. Administration and management activities

- Weekly meetings between the Chair of the Board and the Project Manager, as well as the Technical Officer took place. The purpose of the meetings was to present the overview of the tasks, update on technological advancements regarding the DDF digital tools (Repository and Map), address any challenges/issues related to the DDF projects and EU-funded projects, and plan next steps.

Evaluation: Overall, these weekly interactions are instrumental in ensuring project success, and promoting a culture of transparency and teamwork.

2. Communication/dissemination activities

- Communication and Dissemination activities were ongoing, with relevant material produced.

Outcomes: We noticed an increase in the number of followers on social media, as well as subscribers in our Newsletter.

Evaluation: Additional communication and dissemination activities will be planned for 2024.

3. Projects

Internal DDF Projects

- [Duchenne Data Repository](#)

The Duchenne Data Repository (DDR) is a data hub that can host a range of data types, including pre-clinical, natural history, clinical trials, patient-generated health data, and others. DDR aims to facilitate the findability of dystrophinopathy data stored in various locations around the world, through the development of metadata catalogs. DDR promotes FAIR data principles and is compliant with all GDPR, security, data protection, and privacy standards and policies.

Outcomes: Updates on security, access and FAIR workflows were implemented in the DDR, tailored to the needs for storage and analysis of the BIND datasets. DDR is being used by the BIND consortium partners to store and exchange datasets. Further, a research proposal was developed aiming at the technological and functional advancement of the tool, describing the relevant tasks, deliverables and timelines.

Project Status: Ongoing

Evaluation: An advanced version of the architecture and functionalities of the DDR were successfully implemented. Further, funding is being sought across biotech and pharma companies.

- [Duchenne Map](#)

Duchenne Map is an online platform connecting Duchenne/Becker Muscular Dystrophy (DMD/BMD) families with their local patient organizations, healthcare providers, care centers, researchers, research institutions, and pharmaceutical companies. Duchenne Map offers a secure and inclusive platform where all stakeholders share reliable information.

Project Status: A research proposal was developed aiming at the technological and functional advancement of the tool, describing the relevant tasks, deliverables and timelines.

Evaluation: Funding is being sought across biotech and pharma companies.

European Projects

- [BIND Project](#)

This EU-funded project connects 19 partners and aims to address learning and behavioral issues in DMD/BMD.

Outcomes: A dedicated database, stored in DDR, was developed, and serves as the central storage of the newly generated BIND datasets. The first datasets of the project were received and stored.

Project Status: Ongoing

Evaluation: DDF in collaboration with LUMC (project partner) is responsible for the implementation of FAIR processes for the BIND datasets and metadata. Security, data protection and data privacy policies are in place for the database and monitored continuously by the DDF Information Security Officer. Connection with the EBRAINS database is planned for 2024.

- [EURO-NMD Registry Hub](#)

The general objective of this EU-funded project is to build a unified Registry Hub for neuromuscular diseases, including undiagnosed patients, and connect with the existing registries.

Outcomes: DDF has been actively participating in the Steering Committee and significantly contributed in the communication/dissemination activities. DDF also participated in technical working group discussions, testing technical features of the Registry and contributing to FAIR workflows planned for interoperability with pilot registries during the lifetime of the project. DDF also contributed to the development of the EURO-NMD Registry paper.

Project Status: Ongoing

Evaluation: Overall, DDF's active involvement and contributions have greatly enriched the project's outcomes and fostered a spirit of collaboration that will benefit all stakeholders involved.

- ERDERA (European Rare Diseases Research Alliance) Partnership

The general objective of this partnership is to improve the health and well-being of the 30 million people living with a rare disease in Europe, by making Europe a world leader in RD research and innovation, to support concrete health benefits to RD patients, through better prevention, diagnosis and treatment.

Outcomes: DDF has been actively participating in the Task Force for the development of the Research Agenda, as well as developing the research proposal.

Project Status: Ongoing

Evaluation: Overall, DDF's active involvement and contributions have greatly enriched the proposed project's tasks and deliverables.

- [MAGIC](#)

The aim of MAGIC is to accelerate the development of gene therapies and genome editing strategies for muscular dystrophies by creating advanced humanized muscle models and innovative gene therapy approaches, ultimately improving the lives of individuals affected by these debilitating diseases.

Outcomes: DDF is leading the WP on Dissemination, Communication and Knowledge management. DDF is coordinating other POs involved in the WP in developing and organizing communication and dissemination activities. DDF is also responsible for the data management and DDR will be the central platform form collecting project data and FAIRifying them.

Project Status: Ongoing

Evaluation: Overall, DDF's active involvement and contributions have greatly enriched patient's perspectives in research design and outputs.

Projects in collaboration with the World Duchenne Organization

- [DMD Emergency Program](#)

The DMD Emergency Program aims to support local patient organizations and communities dealing with unexpected emergencies.

Outcomes: Supported emergencies in Ukraine, Turkey and Mexico.

Project Status: Ongoing

Evaluation: New funding was received for future emergencies.

- Stronger Together Project

The Stronger Together Project aims to promote education within the global community.

Outcomes: The project includes the Duchenne Patient Academy and besides this many local events, focus groups, contents and international events have been developed. This educational initiative is a success.

Project Status: close to the end (October 2024).

- [Duchenne CAB](#)

The Duchenne CAB is an international board consisting of independent, autonomous, and trained patient representatives. The goal is to provide its collective knowledge and expertise to accelerate research, development, clinical trials, and access to effective treatments for DMD and BMD worldwide.

Outcomes: The Duchenne CAB held 22 meetings with companies in the period 2022-2023.

Project Status: Ongoing

Evaluation: The Duchenne CAB continues to offer meaningful support to companies to promote better treatment and patient-centered research.

Conclusions

In 2023, DDF participated and co-led several international projects to the benefit of the DMD community. These projects advanced successfully and addressed several aspects of interest to the dystrophinopathy community, including optimal sharing of research and clinical data, training of patient advocates, and creation of digital applications to facilitate discoverability of and accessibility to dystrophinopathy data. DDF is advancing and continuously enriching its activities to improve the world of dystrophinopathies.

ANNUAL ACCOUNTS 2023

Stichting Duchenne Data Foundation, Bergen op Zoom

1 BALANCE SHEET AS AT DECEMBER 31, 2023
(after result appropriation)

	December 31, 2023		December 31, 2022	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Tangible fixed assets (1)		2,435		3,053
CURRENT ASSETS				
Receivables, prepayments and accrued income (2)				
Account receivable	54,000		93,010	
Other receivables, deferred assets	15,281		15,138	
		69,281		108,148
Cash and cash equivalents (3)		283,885		280,069
		<u>355,601</u>		<u>391,270</u>

	December 31, 2023		December 31, 2022	
	€	€	€	€
EQUITY AND LIABILITIES				
RESERVES AND FUNDS (4)				
Unrestricted funds, designated	250,000		250,000	
Unrestricted funds, general	15,144		63,358	
Designated reserve projects	63,282		28,684	
		328,426		342,042
CURRENT LIABILITIES (5)				
Account payable	1,848		1,652	
Taxes and social securities	19,322		38,667	
Other liabilities and Accruals and deferred income	6,005		8,909	
		27,175		49,228
		<u>355,601</u>		<u>391,270</u>

2 STATEMENT OF THE FINANCIAL ACTIVITIES OVER 2023

	Balance 2023	Balance 2022
	€	€
Income		
Income from individuals	(6) 188,310	130,000
Subsidies	(7) 125,627	34,309
Other income	(8) 182,566	177,416
Sum of income	496,503	341,725
Expenses		
Expenditure on activities	434,086	305,443
Costs of support		
Amortisation and depreciation	618	36
Office expenses	(11) 33,160	82,296
General expenses	(12) 42,255	44,285
	76,033	126,617
Balance before financial income and expense	-13,616	-90,335
Financial income and expenses	(13) -	-1,352
Result	-13,616	-91,687
Appropriation of the results		
Unrestricted funds, general	-48,214	-88,209
Designated reserve projects	34,598	-3,478
	-13,616	-91,687

3 NOTES TO THE FINANCIAL STATEMENTS

GENERAL

Activities

The activities of Stichting Duchenne Data Foundation (CoC file 64601188), with registered offices in Bergen op Zoom, mainly consist of the following: The worldwide collaboration between Duchenne Parent Organizations in order to improve the understanding of the course of disease process, the effect of treatment methods, the needs and preferences and all other aspects of all those affected by Duchenne muscular dystrophy (DMD and BMD).

Registered office, legal form and registration number at the chamber of commerce

The registered and actual address of Stichting Duchenne Data Foundation is Warmoesdreef 10, 4614 HC, in Bergen op Zoom of business and is registered at the chamber of commerce under number 64601188.

Estimates

In applying the principles and policies for drawing up the financial statements, the directors of Stichting Duchenne Data Foundation make different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under Book 2, article 362, paragraph 1, the nature of these estimates and judgments, including related assumptions, is disclosed in the notes to the relevant financial statement item.

GENERAL ACCOUNTING PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The annual accounts have been prepared in accordance with the guidelines for annual reporting for small organisations without profit motive (Rjk C1). These are in line with the requirements for small legal entities that fall under Title 9 Book 2 of the Dutch Civil Code.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

Income and expenses are allocated to the year to which they relate. Profits are only included insofar as they have been realized on the balance sheet date. Liabilities and possible losses that originate before the end of the reporting year are taken into account if they have become known before the preparation of the annual accounts.

ACCOUNTING PRINCIPLES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

General

Tangible fixed assets

De materiële vaste activa worden gewaardeerd op verkrijgingsprijs, verminderd met de cumulatieve afschrijvingen en indien van toepassing met bijzondere waardeverminderingen. De afschrijvingen worden gebaseerd op de geschatte economische levensduur en worden berekend op basis van een vast percentage van de verkrijgingsprijs, rekening houdend met een eventuele residuwaarde. Er wordt afgeschreven vanaf het moment van ingebruikneming. Op terreinen wordt niet afgeschreven.

Securities

Upon initial recognition the receivables on and loans to participations and other receivables are valued at fair value and then valued at amortised cost, which equals the face value, after deduction of any provisions. The fair value and amortised cost equal the face value. Any provisions for the risk of doubtful debts are deducted. These provisions are determined based on individual assessment of the receivables.

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

Reserves en fondsen

Unrestricted funds, designated

The Unrestricted funds, designated are reserves with a more limited spending option, whereby the limitation is made by the board. The nature of the limitation is explained later.

Designated reserve projects

De bestemmingsfondsen zijn reserveringen waarbij door een derden een beperktere bestedingsmogelijkheid is aangebracht. De aard van het bestemmingsfonds wordt later toegelicht.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received taking into account premiums or discounts and minus transaction costs. This is usually the nominal value.

ACCOUNTING PRINCIPLES FOR THE DETERMINATION OF THE RESULT

Determination of the result

The result is determined based upon the difference between the nett income and the costs and other expenses taking into account the aforementioned valuation principles.

Income from individuals

Income from private individuals an private companies are general donations for the foundation

Subsidies

Operating subsidies are recorded as income in the profit and loss account in the year in which the subsidised costs were incurred or income was lost or when there was a subsidised operating deficit. Income is recognised when it is probable that it will be received.

Subsidies related to investments in tangible fixed assets are deducted from the asset to which they relate and recorded in the profit and loss account as part of the amortisation costs.

Expenditure on activities

The expenditure on activities consists of the cost directly related to the activities.

Gross margin

The gross operating profit and loss comprises net turnover, the changes in inventories of finished goods and work in progress, work performed by the entity and capitalised, other operating income, cost price and cost of outsourced work and other external charges.

Expenses general

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.

Employee expenses

The benefits payable to personnel are recorded in the profit and loss account on the basis of the employment conditions.

The personnel costs are fully allocated to Patient Academy.

Financial income and expenses

Interest income and interest expenses

Interest income and expenses are recognised on a pro rata basis, taking account of the effective interest rate of the assets and liabilities to which they relate. In accounting for interest expenses, the recognised transaction expenses for loans received are taken into consideration.

4 NOTES TO THE BALANCE SHEET AS OF DECEMBER 31, 2023

ASSETS

	<u>12/31/2023</u>	<u>12/31/2022</u>
	€	€
1. Tangible fixed assets		
Office inventory	2,435	3,053

	<u>Office inventory</u>
	€
<i>Carrying amount as of January 1, 2023</i>	
Purchase price	3,089
Cumulative depreciation and impairment	-36
	<u>3,053</u>

<i>Movement</i>	
Depreciation	<u>-618</u>

<i>Carrying amount as of December 31, 2023</i>	
Purchase price	3,089
Cumulative depreciation and impairment	-654
	<u>2,435</u>

<i>Depreciation rates</i>	
Office inventory	20

2. Receivables, prepayments and accrued income

	<u>12/31/2023</u>	<u>12/31/2022</u>
	€	€
<i>Account receivable</i>		
Account receivable	54,000	93,010

<i>Other receivables and prepayments</i>		
Current account WDO	14,176	14,176
Other receivables	143	-
Insurance	962	962
	<u>15,281</u>	<u>15,138</u>

Stichting Duchenne Data Foundation, Bergen op Zoom

	<u>12/31/2023</u>	<u>12/31/2022</u>
	€	€
3. Cash and cash equivalents		
NL75ABNA0620549920	260,266	280,069
NL05ABNA0120670798	<u>23,619</u>	<u>-</u>
	<u><u>283,885</u></u>	<u><u>280,069</u></u>

The liquid resources are valued at nominal value. The liquid resources available as at December 31, 2023 are freely available to the Stichting Duchenne Data Foundation.

EQUITY AND LIABILITIES

	<u>12/31/2023</u>	<u>12/31/2022</u>
	€	€
4. Reserves and funds		
Unrestricted funds, designated	250,000	250,000
Unrestricted funds, general	15,144	63,358
Designated reserve projects	63,282	28,684
	<u>328,426</u>	<u>342,042</u>
Unrestricted funds, designated		
Selfinitiated Projects	100,000	100,000
Continuity reserves	150,000	150,000
	<u>250,000</u>	<u>250,000</u>
	<u>2023</u>	<u>2022</u>
	€	€
<i>Selfinitiated Projects</i>		
Carrying amount as of January 1	100,000	100,000
Carrying amount as of December 31	<u>100,000</u>	<u>100,000</u>
<i>Continuity reserves</i>		
Carrying amount as of January 1	150,000	150,000
Carrying amount as of December 31	<u>150,000</u>	<u>150,000</u>
<i>Unrestricted funds, general</i>		
Carrying amount as of January 1	63,358	151,567
Allocation of financial year net result	-48,214	-88,209
Carrying amount as of December 31	<u>15,144</u>	<u>63,358</u>
	<u>12/31/2023</u>	<u>12/31/2022</u>
	€	€
Designated reserve projects		
Designated reserve projects - MAGIC	51,829	-
Designated reserve projects - BIND	11,453	28,684
	<u>63,282</u>	<u>28,684</u>

Stichting Duchenne Data Foundation, Bergen op Zoom

	Carrying amount as of January 1	Result allocation	Carrying amount as of December 31
	€	€	€
Designated reserve projects - MAGIC	-	51,829	51,829
Designated reserve projects - BIND	28,684	-17,231	11,453
	<u>28,684</u>	<u>34,598</u>	<u>63,282</u>
		<u>12/31/2023</u>	<u>12/31/2022</u>
	€	€	
<u>Designated reserve projects - MAGIC</u>			
Carrying amount as of January 1	-	-	-
Result allocation		51,829	-
Carrying amount as of December 31		<u>51,829</u>	<u>-</u>
<u>Designated reserve projects - BIND</u>			
Carrying amount as of January 1	28,684	-	32,162
Result allocation		-17,231	-3,478
Carrying amount as of December 31		<u>11,453</u>	<u>28,684</u>

5. Current liabilities

	<u>12/31/2023</u>	<u>12/31/2022</u>
	€	€
<i>Account payable</i>		
Account payable	<u>1,848</u>	<u>1,652</u>
<i>Taxes and social securities</i>		
VAT	20,848	38,048
Pay-roll tax	<u>-1,526</u>	<u>619</u>
	<u>19,322</u>	<u>38,667</u>
<i>VAT</i>		
VAT last period 2023	11,743	20,406
VAT supplementation 2023	-8,537	-
VAT supplementation 2021	11,865	11,865
VAT supplementation 2020	<u>5,777</u>	<u>5,777</u>
	<u>20,848</u>	<u>38,048</u>
<i>Pay-roll tax</i>		
Pay-roll tax	1,526	619
Pay-roll tax august and october 2023 paid too much	<u>-3,052</u>	<u>-</u>
	<u>-1,526</u>	<u>619</u>
<i>Other liabilities and Accruals and deferred income</i>		
Audit costs	<u>6,005</u>	<u>8,909</u>

5 NOTES TO THE STATEMENT OF FINANCIAL ACTIVITIES 2023

	Balance 2023	Balance 2022
	€	€
6. Income from individuals		
Donations	188,310	130,000
7. Subsidies		
European Commission subsidy BIND	32,060	34,309
European Commission subsidy MAGIC project	93,567	-
	<u>125,627</u>	<u>34,309</u>
8. Other income		
Income Community Advisory Board	167,566	177,416
Stronger together project	15,000	-
	<u>182,566</u>	<u>177,416</u>
9. Expenditure on activities		
Costs of congress and seminars	6,223	2,047
Costs of Community Advisory Board	64,822	63,949
Costs of MAP	670	10,428
Costs of MAGIC project	41,738	-
Costs of Stronger together project	44,016	-
Costs of Patient Academy	93,939	36,649
Costs of Psycho Project	3,782	6,275
Costs of Meeting Rome	6,192	-
Costs of EURO NMD	8,400	3,960
Costs of Digital D&B Program	23,362	18,523
Costs of DDF Repository	-	35,054
Costs of BIND	49,291	37,787
Costs of FAIR	-	212
Costs of WDAD	-	12,000
Costs of Emergency Programm	81,083	20,182
Costs of Communication	10,568	58,377
	<u>434,086</u>	<u>305,443</u>
10. Employee expenses		
Wages and salaries	34,062	13,862
Social security charges	5,787	2,336
Other personnel costs	-39,849	-16,198
	<u>-</u>	<u>-</u>
<i>Wages and salaries</i>		
Gross wages	31,647	12,835
Gross holidaypay	2,415	1,027
	<u>34,062</u>	<u>13,862</u>
<i>Social security charges</i>		
Other social charges	<u>5,787</u>	<u>2,336</u>

Stichting Duchenne Data Foundation, Bergen op Zoom

	Balance 2023	Balance 2022
	€	€
<i>Other personnel costs</i>		
Travelling expenses	2,966	894
Allocated labour costs Patient Academy	-42,815	-17,092
	<u>-39,849</u>	<u>-16,198</u>
Staff		
During 2023 1 employee was employed on a full-time basis.(2022: 1)		
Amortisation and depreciation		
<i>Depreciation of tangible fixed assets</i>		
Office inventory	618	36
	<u>618</u>	<u>36</u>
Other operating expenses		
11. Office expenses		
Automation costs	33,160	82,296
12. General expenses		
Audit costs	14,027	8,130
Auditcosts previous years	-	3,409
consultancy fees	-	450
Insurance costs	1,011	1,011
Bank costs	896	574
Non-deductible VAT	26,355	30,739
Other general expenses	-34	-28
	<u>42,255</u>	<u>44,285</u>
13. Financial income and expenses		
Interest and similar expenses	-	-1,352
<i>Interest and similar expenses</i>		
Other interest payable	-	-1,352

OTHER INFORMATION

OTHER INFORMATION

1 Audit

your company has utilized the exemption from an audit by virtue of art. 2:396, paragraph 7 of the Dutch Civil Code.

2 Recognition of the loss for 2023

The board of directors proposes to add the 2023 result to the other reserves for an amount of € 13,616. The General Meeting of Shareholders will be asked to approve the appropriation of the 2023 result, this proposition is already recognised in the financial statements.

Gegevens bedrijf

Onderneming Stichting Duchenne Data Foundation
Btw-nummer NL855738807B01
Tijdvak Jaar

	Bedrag waarover omzetbelasting wordt berekend Omzetbelasting	
	€	€
1: Prestaties binnenland		
1a: Leveringen/diensten belast met hoog tarief	0	0
1b: Leveringen/diensten belast met laag tarief	0	0
1c: Leveringen/diensten belast met overige tarieven, behalve 0%	0	0
1d: Privégebruik	0	0
1e: Leveringen/diensten belast met 0% of niet bij Stichting Duchenne Data Foundation belast	0	
2: Verleggingsregeling binnenland		
2a: Leveringen/diensten waarbij de omzetbelasting naar Stichting Duchenne Data Foundation is verlegd	0	0
3: Prestaties naar of in het buitenland		
3a: Leveringen naar landen buiten de EU (uitvoer)	0	
3b: Leveringen naar of diensten in landen binnen de EU	0	
3c: Installatie/afstandsverkopen binnen de EU	0	
4: Prestaties vanuit het buitenland aan u geleverd		
4a: Leveringen/diensten uit landen buiten de EU	2.662	559
4b: Leveringen/diensten uit landen binnen de EU	119.271	25.047
5: Voorbelasting en kleineondernemersregeling		
5a: Verschuldigde omzetbelasting		25.606
5b: Voorbelasting		-4.905
Saldo eerder opgegeven		-29.238
Te ontvangen omzetbelasting		8.537